WCN26-3469 Binutuzumab induces histologic remission and deep kidney parenchymal b-cell depletion in patients with lupus nephritis: exploratory analyses from the regency trial

Rovin, Brad H.; Martins, Elsa; Austin, Cary D.; Raghu, Harini; Chan, Caleb; Chang, Patrick; Alberton, Valeria; Santiago, Mittermayer; Aroca-Martinez, Gustavo; Alfaro, Jose; Furie, Richard A.; Larson, Christopher; Yoo, Bongin; Pendergraft, William F.; Malvar, Ana

WCN26-3469 Binutuzumab induces histologic remission and deep kidney parenchymal b-cell depletion in patients with lupus nephritis: exploratory analyses from the regency trial

Archivos

PDF.pdf (1.21 MB)

Fecha

2026

Autores

Rovin, Brad H.

Martins, Elsa

Austin, Cary D.

Raghu, Harini

Chan, Caleb

Chang, Patrick

Alberton, Valeria

Santiago, Mittermayer

Aroca-Martinez, Gustavo

Alfaro, Jose

Editor

International Society of Nephrology ISN

Resumen

The REGENCY trial (NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at Week 76 (W76) in adults with active lupus nephritis (LN). It was postulated that OBI+ST would yield greater rates of histologic remission and kidney tissue-level B-cell depletion at W76 than PBO+ST, which would portend more favorable long-term kidney outcomes, such as reduced LN flare risk and preserved kidney function. These exploratory analyses aimed to evaluate histologic remission and kidney tissue-level B-cell depletion at W76 in patients treated with OBI+ST vs PBO+ST.